Description

This issue of Vital Signs, released on August 25, 2008, provides an strategic overview of challenges relevant to drug delivery product design, valuation and commercial opportunity assessment for pharmaceutical & biotechnology companies. Additionally, a company spotlight is provided for Novocell, a stem cell engineering company dedicated to development, creation and commercialization of cell and drug based therapies for diabetes and other chronic diseases. Reimbursement and regulatory news from the FDA is also provided for the week of August 11, 2008.